On May 30, a Phase II head-to-head trial ARACOG trial shows significantly less executive and working memory decline compared to enzalutamide.
The report adds that bayer presented ASCO 2026 data showing NUBEQA produced superior cognitive outcomes in advanced prostate cancer.
The Phase II ARACOG trial recorded less executive and working memory decline versus enzalutamide.
Oncologists highlighted cognitive preservation as a secondary endpoint in the head-to-head comparison. The account draws on verified materials available as of May 30, 2026.
According to available records, patient-reported outcomes aligned with neurocognitive testing results favoring NUBEQA.
Named entities in source reporting include Bayer, NUBEQA, ASCO 2026.
Source documents list dates, agencies, and procedural steps referenced in the summary above.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.bayer.com/en/us/news-stories/new-findings-for-nubeqa